LOW-DOSE CYTARABINE AFTER FAILURE OF 5-AZACITIDINE AS PALLIATIVE TREATMENT FOR ELDERLY PATIENTS WITH AML OR HIGH-RISK MDS INELIGIBLE FOR INTENSIVE CHEMOTHERAPY. A RETROSPECTIVE SINGLE CENTER ANALYSIS

被引：0
|
作者：
Jakob, C. [1 ]
Peinert, S.
Breywisch, F. [1 ]
Guenther, B. [1 ]
Dittberner, K. [1 ]
Boger, L. [1 ]
Rothmann, F. [1 ]
Maschmeyer, G. [1 ]
机构：
[1] Klinikum Ernst Bergmann, Hematol Oncol & Pallait Care, Potsdam, Germany
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E967
引用
收藏
页码：386 / 386
页数：1
相关论文
共 43 条
  • [41] Low-Dose Clofarabine Has Significant Activity in High-Risk Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia Post-MDS (sAML) After Azacitidine (AZA) Failure: Interim Results of the GFM Clo08 Dose Escalating Phase I/II Study (NCT0106325)
    Braun, Thorsten
    Raffoux, Emmanuel
    Prebet, Thomas
    Brechignac, Sabine
    Stamatoullas, Aspasia
    Dreyfus, Francois
    Hebibi, Zehaira
    Ades, Lionel
    Vey, Norbert
    Dombret, Herve
    Fenaux, Pierre
    Cardin, Claude
    BLOOD, 2011, 118 (21) : 279 - 280
  • [42] Hematopoietic cell transplantation (HCT) after low-dose, total body irradiation-based regimen increased leukemia-free survival (LFS) in elderly patients with cytogenetic high-risk AML compared to chemotherapy (OSHO 97 study)
    Niederwieser, D.
    Becker, C.
    Krahl, R.
    Al-Ali, H.
    Lange, T.
    Gerhardt, A.
    Schulze, A.
    Haehling, D.
    Schulze, M.
    Freund, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [43] 131I-anti-CD45 antibody plus fludarabine, low-dose total body irradiation and peripheral blood stem cell infusion for elderly patients with advanced acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS).
    Pagel, JM
    Appelbaum, FR
    Sandmaier, BM
    Rajendran, JG
    Gooley, T
    Fisher, DR
    Nemecek, E
    Gopal, AK
    Maris, MB
    Ruffner, K
    Matthews, DC
    Deeg, HJ
    Maloney, DG
    Martin, PJ
    Storb, R
    BLOOD, 2005, 106 (11) : 119A - 119A
12345